OnKure Therapeutics, Inc.
OKURNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for OKUR. That does not mean none is planned.
Get an email about OKUR's next catalysts
Track OnKure Therapeutics (OKUR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming events in our data (earnings, trial start).See the timeline
2 upcoming, 1 past
OKUR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.29 | FQ end Sep/2026 | Call: tbd
Trial Start
OnKure Therapeutics is advancing allosteric PI3KΞ± inhibitor drugs with IND application targets anticipated in 2027.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OKI-179 + binimetinib | Phase 2 | RAS Mutation | - | - |
Frequently asked questions
What is in OnKure Therapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in OnKure Therapeutics, Inc.'s (OKUR) pipeline across Phase 2. Its lead program is OKI-179 + binimetinib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OnKure Therapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for OnKure Therapeutics, Inc. (OKUR) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track OKUR biotech catalysts?β
Add OKUR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OnKure Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.